Optical coherence tomography changes before the development of choroidal neovascularization in second eyes of patients with bilateral wet macular degeneration

Amissah-Arthur, Kwesi N; Panneerselvam, Swathi; Narendran, Niro; Yang, Yit

doi:10.1038/eye.2011.335

Cited by 33 publications

(27 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, the most prevalent clinical finding was the presence of IRF and/or SRF imaged with OCT, and in 33% of patients, this was the only clinical indicator of nAMD in the second eye at baseline. Previous studies have shown that OCT fluid is a reliable marker of active nAMD [23] and OCT changes can be sudden and unpredictable [24] .…”

Section: Discussionmentioning

confidence: 99%

Bilateral Neovascular Age-Related Macular Degeneration: Comparisons between First and Second Eyes

Chew¹,

Zhu²,

Broadhead³

et al. 2017

Ophthalmologica

View full text Add to dashboard Cite

Purpose: To compare 12-month outcomes and clinical presentations between first and second eyes of patients who developed neovascular age-related macular degeneration (nAMD) in both eyes and received ranibizumab intravitreal therapy (IVT). Methods: This is a retrospective case series of 45 patients undergoing IVT for unilateral nAMD who subsequently developed second-eye nAMD. At each visit, both eyes underwent visual acuity (VA) measurement and optical coherence tomography (OCT). Results: In second eyes, 53% were asymptomatic at baseline, with OCT retinal fluid as the only sign of nAMD among 33% of patients. In eyes with baseline VA >6/9, 82% of second treated eyes maintained this vision versus 12% of first eyes (p = 0.05). At 12 months, 70% of second eyes were fluid free versus 41% of first eyes (p = 0.02). Conclusions: A large proportion of patients are asymptomatic at diagnosis of second-eye nAMD. Early intervention following earlier detection of nAMD in the second eye may lead to improved clinical outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Bilateral Neovascular Age-Related Macular Degeneration: Comparisons between First and Second Eyes

Chew¹,

Zhu²,

Broadhead³

et al. 2017

Ophthalmologica

View full text Add to dashboard Cite

show abstract

“…AMD is a bilateral disease, and risk of neovascularization in a fellow eye increases over time after initial diagnosis [12]. Hence, it is important to determine the status of both eyes at diagnosis.…”

Section: Discussionmentioning

confidence: 99%

Baseline Characteristics of the Fellow Eye in Patients with Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of the VIEW Studies

Wolf

Bandello

Loewenstein³

et al. 2016

Ophthalmologica

View full text Add to dashboard Cite

Purpose: The aim was to describe baseline characteristics of the fellow eye of patients with neovascular age-related macular degeneration (nAMD). Methods: A pooled, post hoc analysis of patients with nAMD enrolled in the VIEW studies was carried out. The VIEW studies compared intravitreal aflibercept (monthly or every 2 months after 3 monthly injections) with monthly ranibizumab. Baseline choroidal neovascularization (CNV) status of fellow eyes and baseline best-corrected visual acuity (BCVA) and lens status of all eyes were evaluated. Additional analyses evaluated the presence of drusen and pigment in fellow eyes. Results: When comparing both eyes, baseline BCVA was worse in 23.8% of fellow eyes and in 75.2% of study eyes. Lens status of fellow eyes and study eyes was similar. Baseline visual acuity of the study eye and that of the fellow eye were not correlated. Most fellow eyes had signs of early AMD, with 34.6% (n = 843) of fellow eyes having evidence of scarring. Conclusions: In patients in the VIEW studies, most fellow eyes had evidence of AMD, highlighting the importance of examining both eyes, with close follow-up thereafter, in order to detect and treat CNV earlier as needed.

show abstract

“…The common recommendation is, therefore, to monitor disease activity using SD-OCT, and on a monthly base. The concept of a ‘zero tolerance’ on OCT criteria is emerging, because of the rapid progression of exudative features and progressive loss of vision when initiation of treatment is delayed 61. However, persistent IRC should be considered signs of irreversible retinal degeneration and should not trigger further retreatment.…”

Section: Introductionmentioning

confidence: 99%

Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)

Schmidt‐Erfurth

Chong

Loewenstein³

et al. 2014

Br J Ophthalmol

528

456

View full text Add to dashboard Cite

Age-related macular degeneration (AMD) is still referred to as the leading cause of severe and irreversible visual loss world-wide. The disease has a profound effect on quality of life of affected individuals and represents a major socioeconomic challenge for societies due to the exponential increase in life expectancy and environmental risks. Advances in medical research have identified vascular endothelial growth factor (VEGF) as an important pathophysiological player in neovascular AMD and intraocular inhibition of VEGF as one of the most efficient therapies in medicine. The wide introduction of anti-VEGF therapy has led to an overwhelming improvement in the prognosis of patients affected by neovascular AMD, allowing recovery and maintenance of visual function in the vast majority of patients. However, the therapeutic benefit is accompanied by significant economic investments, unresolved medicolegal debates about the use of off-label substances and overwhelming problems in large population management. The burden of disease has turned into a burden of care with a dissociation of scientific advances and real-world clinical performance. Simultaneously, ground-breaking innovations in diagnostic technologies, such as optical coherence tomography, allows unprecedented high-resolution visualisation of disease morphology and provides a promising horizon for early disease detection and efficient therapeutic follow-up. However, definite conclusions from morphologic parameters are still lacking, and valid biomarkers have yet to be identified to provide a practical base for disease management. The European Society of Retina Specialists offers expert guidance for diagnostic and therapeutic management of neovascular AMD supporting healthcare givers and doctors in providing the best state-of-the-art care to their patients.Trial registration numberNCT01318941.

show abstract

Optical coherence tomography changes before the development of choroidal neovascularization in second eyes of patients with bilateral wet macular degeneration

Cited by 33 publications

References 17 publications

Bilateral Neovascular Age-Related Macular Degeneration: Comparisons between First and Second Eyes

Bilateral Neovascular Age-Related Macular Degeneration: Comparisons between First and Second Eyes

Baseline Characteristics of the Fellow Eye in Patients with Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of the VIEW Studies

Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)

Contact Info

Product

Resources

About